Teva's drug Orzfull (TK861) is mentioned as a competitor to Harmony Biosciences' BP 205, serving as validation for the orexin 2 agonist mechanism but noted for its lower potency and twice-daily dosing requirement.
Source Post
Deep Dive: Is Harmony Biosciences a Value Trap or a Multi-Bagger? (HRMY)
Aug 29, 2026
The creator discusses Harmony Biosciences (HRMY), a biotech company focused on rare neurological diseases. They highlight a significant disconnect between the company's strong profitability and market perception, suggesting Wall Street is overly anxious and mispricing the stock. The strategy of focusing on niche patient populations is presented as highly lucrative due to reduced competition and regulatory incentives, leading to exceptional margins for a company of Harmony's size.
Linked Mentions
Tickers discussed in this post
Harmony Biosciences (HRMY) is presented as a company with a bizarre valuation disconnect, trading like it's going bankrupt despite being highly profitable, suggesting a potential buying opportunity.
Linked Signals
Tracked calls opened from this post
HRMYbuy opened Aug 29, 2026
-4.82%